| Species |
Mouse |
| Protein Construction |
HPN (Thr60-Pro436)_x000D_
Accession # O35453-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
42.2 kDa |
| Apparent Molecular Weight |
Due to the protein cleaved into the following two chains, so it migrates to 18-22 kDa and 30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM NaAc,150mM NaCl (pH 5.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM NaAc,150mM NaCl (pH 5.0). |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Home parenteral nutrition (HPN) has been proposed as the treatment of choice in patients suffering from intestinal failure (IF) and has been claimed to improve survival and quality of life either in patients with benign disorders or even in those with malignancies. HPN seems to have beneficial effect but it should be considered with caution by the physicians who should take into account the indications of each patient to receive parenteral nutrition, the underlying disease and prognosis and the access of each patient to home care services. |
| Synonyms |
Serine protease hepsin; TMPRSS1; Hepsin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
